Literature DB >> 28463663

Prevalence of Burkholderia species, including members of Burkholderia cepacia complex, among UK cystic and non-cystic fibrosis patients.

Dervla T D Kenna1, Daniel Lilley1, Amy Coward1, Kate Martin1, Claire Perry1, Rachel Pike1, Robert Hill1, Jane F Turton1.   

Abstract

PURPOSE: We aimed to establish the prevalence of different Burkholderia species among UK cystic fibrosis (CF) and non-CF patients over a 2 year period.
METHODOLOGY: Matrix-assisted laser desorption/ionization-time of flight mass spectrometry was used to identify isolates to genus level, followed by recA/gyrB sequence clustering or species-specific PCR. In all, 1047 Burkholderia isolates were submitted for identification from 361 CF patients and 112 non-CF patients, 25 from the hospital environment and three from a commercial company. Potential cross-infection was assessed by pulsed-field gel electrophoresis (PFGE) and multi- locus-sequence typing (MLST). MICs were determined for 161 Burkholderia cepacia complex (Bcc) isolates. CF Trust registry data were sought to examine clinical parameters relating to Bcc infection.
RESULTS: Burkholderia multivorans was the most prevalent species among CF patients affecting 56 % (192) patients, followed by Burkholderia cenocepacia IIIA (15 %; 52 patients). Five novel recA clusters were found. Among non-CF patients, Burkholderia cepacia was the most prevalent species (37/112; 34 %), with 18 of 40 isolates part of a UK-wide B. cepacia 'cluster'. This and three other clusters were investigated by PFGE and MLST. Cable-pili positive isolates included two novel sequence types and representatives of ET12. Antibiotic susceptibility varied between and within species and CF/non- CF isolates. CF Trust registry data suggested no significant difference in lung function between patients harbouring B. cenocepacia, B. multivorans and other Bcc species (P=0.81).
CONCLUSION: The dominance of B. multivorans in CF, the presence of a B. cepacia cluster among non-CF patients and the existence of putative novel species all highlighted the continuing role of Burkholderia species as opportunistic pathogens.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28463663     DOI: 10.1099/jmm.0.000458

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  22 in total

Review 1.  Decreasing the Cut-off Score Value of MALDI-ToF MS Increase the Identities of Burkholderia cepacia Complex Species.

Authors:  Edgard de Freitas Vianna; Ludimila Santos da Silva Pentagna; Nicoli Izzy Miotto Menezes; Flávia Alvim Dutra de Freitas; Cassiana da Costa Ferreira Leite; Rodolpho Mattos Albano; Robson Souza Leão; Elizabeth Andrade Marques
Journal:  Curr Microbiol       Date:  2021-05-04       Impact factor: 2.188

2.  16S rDNA and ITS Sequence Diversity of Burkholderia mallei Isolated from Glanders-Affected Horses and Mules in India (2013-2019).

Authors:  Karuppusamy Shanmugasundaram; Harisankar Singha; Sheetal Saini; Bhupendra N Tripathi
Journal:  Curr Microbiol       Date:  2021-12-18       Impact factor: 2.188

3.  Methionine dietary supplementation potentiates ionizing radiation-induced gastrointestinal syndrome.

Authors:  Isabelle R Miousse; Laura E Ewing; Charles M Skinner; Rupak Pathak; Sarita Garg; Kristy R Kutanzi; Stepan Melnyk; Martin Hauer-Jensen; Igor Koturbash
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-21       Impact factor: 4.052

4.  Activity of Aerosolized Levofloxacin against Burkholderia cepacia in a Mouse Model of Chronic Lung Infection.

Authors:  Mojgan Sabet; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

5.  Influence of relevant cystic fibrosis bacteria on Scedosporium apiospermum and Scedosporium boydii growth and viability.

Authors:  Andressa de Jesus Marques; Rodrigo Rollin-Pinheiro; Mariana Ingrid Dutra da Silva Xisto; André Luis Souza Dos Santos; Eliana Barreto-Bergter; Livia Cristina Liporagi-Lopes
Journal:  Braz J Microbiol       Date:  2021-01-13       Impact factor: 2.476

6.  Ralstonia infection in cystic fibrosis.

Authors:  H D Green; R Bright-Thomas; D T Kenna; J F Turton; N Woodford; A M Jones
Journal:  Epidemiol Infect       Date:  2017-08-09       Impact factor: 4.434

Review 7.  Role of inflammation and oxidative stress in tissue damage associated with cystic fibrosis: CAPE as a future therapeutic strategy.

Authors:  Victor Emanuel Miranda Soares; Thiago Inácio Teixeira do Carmo; Fernanda Dos Anjos; Jonatha Wruck; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini; Débora Tavares de Resende E Silva
Journal:  Mol Cell Biochem       Date:  2021-09-16       Impact factor: 3.396

8.  Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.

Authors:  Robert Lord; Andrew M Jones; Alex Horsley
Journal:  Cochrane Database Syst Rev       Date:  2020-04-02

9.  Antimicrobial activity of essential oils against multidrug-resistant clinical isolates of the Burkholderia cepacia complex.

Authors:  Lakshmi Vasireddy; Lewis E H Bingle; Mark S Davies
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

10.  A Novel Inducible Prophage from Burkholderia Vietnamiensis G4 is Widely Distributed across the Species and Has Lytic Activity against Pathogenic Burkholderia.

Authors:  Rebecca Weiser; Zhong Ling Yap; Ashley Otter; Brian V Jones; Jonathan Salvage; Julian Parkhill; Eshwar Mahenthiralingam
Journal:  Viruses       Date:  2020-05-31       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.